Surface Oncology to Participate in Novel Immuno-Oncology Panel at Cowen’s 42nd Annual Health Care Conference
Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company, announced that CEO Rob Ross, M.D., will participate in the “Novel Immuno-Oncology” panel at Cowen’s 42nd Annual Health Care Conference on March 7, 2022, at 10:30 a.m. ET. The discussion will be accessible via a live webcast on the company's website, with an archived replay available for 30 days post-conference. Surface Oncology is focused on developing next-generation therapies targeting the tumor microenvironment, including clinical-stage programs and collaborations with major pharmaceutical companies.
- None.
- None.
CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Rob Ross, M.D., chief executive officer, will participate in the “Novel Immuno-Oncology” panel discussion at Cowen’s 42nd Annual Health Care Conference on Monday, March 7, 2022 at 10:30 a.m. ET.
A live webcast of the panel discussion will be accessible from the Events & Presentations page of the company's website. A subsequent archived replay of the session will be available on the website for 30 days following the end of the conference.
About Surface Oncology
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment. Its pipeline includes two wholly-owned clinical-stage programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). In addition, Surface has two partnerships with major pharmaceutical companies: a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (GSK4381562; IND filed). Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. For more information, please visit www.surfaceoncology.com.
Contact
Scott Young
(617) 865-3250
syoung@surfaceoncology.com
FAQ
What is the date and time of the Surface Oncology panel discussion at Cowen’s 42nd Annual Health Care Conference?
What is the focus of Surface Oncology's research?
Where can I watch the Surface Oncology panel discussion?
How long will the archived replay of the Surface Oncology panel discussion be available?
Who is participating in the Surface Oncology panel discussion?
